Vertex Pharmaceuticals Inc. (VRTX)

166.31
0.14 0.08
NASDAQ : Health Technology
Prev Close 166.17
Open 168.06
Day Low/High 165.17 / 169.62
52 Wk Low/High 144.07 / 194.92
Volume 559.79K
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 255.56M
Market Cap 44.32B
EPS 1.10
P/E Ratio 67.75
Div & Yield N.A. (N.A)

Latest News

Monday Madness: Ready to Add Some Stocks to Your Holiday Wishlist?

Monday Madness: Ready to Add Some Stocks to Your Holiday Wishlist?

Here's what you're missing on TheStreet.

Top Analysts: Five 'Strong Buy' Stocks for 2019

Top Analysts: Five 'Strong Buy' Stocks for 2019

These 5 hot stocks will deliver outsized gains in 2019, say best-performing analysts

Vertex Announces European Commission Approval For KALYDECO® (ivacaftor) To Treat Patients With Cystic Fibrosis Aged 12 To <24 Months With Certain Mutations In The CFTR Gene

Vertex Announces European Commission Approval For KALYDECO® (ivacaftor) To Treat Patients With Cystic Fibrosis Aged 12 To <24 Months With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for KALYDECO ® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at...

Vertex Pharmaceuticals Becomes #45 Most Shorted Nasdaq 100 Component, Replacing Intuit

Vertex Pharmaceuticals Becomes #45 Most Shorted Nasdaq 100 Component, Replacing Intuit

The most recent short interest data has been released for the 11/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Two Phase 3 Studies Of The Triple Combination Of VX-659, Tezacaftor And Ivacaftor Met Primary Endpoint Of Improvement In Lung Function (ppFEV1) In People With Cystic Fibrosis

Two Phase 3 Studies Of The Triple Combination Of VX-659, Tezacaftor And Ivacaftor Met Primary Endpoint Of Improvement In Lung Function (ppFEV1) In People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with the triple combination of the next-generation corrector VX-659, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function (percent...

Vertex Receives European CHMP Positive Opinion For ORKAMBI&reg; (lumacaftor/ivacaftor) For Treatment Of Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Vertex Receives European CHMP Positive Opinion For ORKAMBI® (lumacaftor/ivacaftor) For Treatment Of Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI ® (lumacaftor/ivacaftor) for the treatment of people with...

Vertex Pharmaceuticals Achieves #43 Analyst Rank, Surpassing NRG Energy

Vertex Pharmaceuticals Achieves #43 Analyst Rank, Surpassing NRG Energy

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Vertex Pharmaceuticals, Inc. has taken over the #43 spot from NRG Energy Inc , according to ETF Channel.

Vertex Announces European Authorization For Third Cystic Fibrosis Medicine SYMKEVI&reg; (tezacaftor/ivacaftor), To Be Used In Combination With Ivacaftor (KALYDECO&reg;), For People With CF Aged 12 And Older With Certain Mutations In The CFTR Gene

Vertex Announces European Authorization For Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), To Be Used In Combination With Ivacaftor (KALYDECO®), For People With CF Aged 12 And Older With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals (Europe) Limited, today announced that the European Commission has granted Marketing Authorization for SYMKEVI ® (tezacaftor/ivacaftor) in a combination regimen with ivacaftor (KALYDECO ®) for the treatment of people with cystic...

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Vertex Reports Third-Quarter 2018 Financial Results

Vertex Reports Third-Quarter 2018 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2018 and reviewed recent progress with its approved and investigational medicines.

Vertex Receives European CHMP Positive Opinion For KALYDECO&reg; (ivacaftor) To Treat Patients With Cystic Fibrosis Aged 12 To &lt;24 Months With Certain Mutations In The CFTR Gene

Vertex Receives European CHMP Positive Opinion For KALYDECO® (ivacaftor) To Treat Patients With Cystic Fibrosis Aged 12 To <24 Months With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO ® (ivacaftor) to include the treatment of people with cystic...

Vertex Data Presented At North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding And Enhancing Options For Treating The Underlying Cause Of Cystic Fibrosis

Vertex Data Presented At North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding And Enhancing Options For Treating The Underlying Cause Of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that eight scientific abstracts from the company's portfolio of cystic fibrosis (CF) medicines are being presented at the 32 nd North American Cystic Fibrosis Conference taking place...

Vertex To Announce Third Quarter 2018 Financial Results On October 24

Vertex To Announce Third Quarter 2018 Financial Results On October 24

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close.

Chart of the Day: Vertex Pharmaceuticals

VRTX is still clinging to the pattern of higher lows.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Vertex To Present At The Morgan Stanley Healthcare Conference On September 14

Vertex To Present At The Morgan Stanley Healthcare Conference On September 14

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.

Vertex Appoints Katharine Jensen As Head Of Corporate Social Responsibility

Vertex Appoints Katharine Jensen As Head Of Corporate Social Responsibility

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Katharine Jensen has been appointed Head of Corporate Social Responsibility (CSR).

Vertex Completes Enrollment Of Two Phase 3 Studies Of VX-659 In Triple Combination With Tezacaftor And Ivacaftor For The Treatment Of Cystic Fibrosis

Vertex Completes Enrollment Of Two Phase 3 Studies Of VX-659 In Triple Combination With Tezacaftor And Ivacaftor For The Treatment Of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that enrollment is complete for the two Phase 3 studies of the next-generation corrector VX-659 in triple combination with tezacaftor and ivacaftor in people with cystic fibrosis (CF) with...

Vertex Announces Reimbursement Agreement In Australia For ORKAMBI&reg; (lumacaftor/ivacaftor) For People With Cystic Fibrosis Ages Six Years And Older With Two Copies Of The F508del Mutation

Vertex Announces Reimbursement Agreement In Australia For ORKAMBI® (lumacaftor/ivacaftor) For People With Cystic Fibrosis Ages Six Years And Older With Two Copies Of The F508del Mutation

Vertex Pharmaceuticals (Europe) Limited announces finalization of an agreement with the Australian Government that allows for reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) for people ages six and over with cystic fibrosis (CF) who have two copies of...

Vertex And Genomics Plc Establish Collaboration To Use Human Genetics And Data Science To Advance Discovery Of Precision Medicines

Vertex And Genomics Plc Establish Collaboration To Use Human Genetics And Data Science To Advance Discovery Of Precision Medicines

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance...

Vertex Appoints Ludovic Fenaux As Senior Vice President, International Commercial Operations

Vertex Appoints Ludovic Fenaux As Senior Vice President, International Commercial Operations

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ludovic Fenaux has been appointed Senior Vice President, International Commercial Operations with responsibility for commercial activities outside of the U.

Vertex Receives A Positive PBAC Recommendation For Reimbursement Of ORKAMBI&reg; (lumacaftor/ivacaftor) To Treat Australians Ages Six And Over With Cystic Fibrosis And Two Copies Of The F508del Mutation

Vertex Receives A Positive PBAC Recommendation For Reimbursement Of ORKAMBI® (lumacaftor/ivacaftor) To Treat Australians Ages Six And Over With Cystic Fibrosis And Two Copies Of The F508del Mutation

Vertex Pharmaceuticals (Europe) Limited announces that it has received the Pharmaceutical Benefits Advisory Committee's (PBAC) recommendation for ORKAMBI ® (lumacaftor/ivacaftor) to be listed on the Pharmaceutical Benefits Scheme (PBS) in Australia for...

Today Was Very Mediocre in Terms of the Rally

For the first time in what seems like forever the tech stocks didn’t lead.

Vertex Awards Two College Students Full Scholarships To The University Of Massachusetts

Vertex Awards Two College Students Full Scholarships To The University Of Massachusetts

Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride scholarship to pursue an education in science, technology, engineering, art or math (STEAM) at any University of Massachusetts campus.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

Vertex Receives European CHMP Positive Opinion For SYMKEVI&reg; (tezacaftor/ivacaftor) For People With Cystic Fibrosis Aged 12 And Older With Certain Mutations In The CFTR Gene

Vertex Receives European CHMP Positive Opinion For SYMKEVI® (tezacaftor/ivacaftor) For People With Cystic Fibrosis Aged 12 And Older With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals (Europe) Limited, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for SYMKEVI ® (tezacaftor/ivacaftor) in a combination regimen with...

TheStreet Quant Rating: B (Buy)